Antibody Discovery Services with Alloy Therapeutics
Today’s economic environment is forcing therapeutic companies to do more with less while maintaining aggressive timelines. Alloy Therapeutics is a drug discovery partner that can take you further faster.
One of our partners that engaged Alloy as a drug discovery partner, is on track to go from discovery to IND in under a year on their first program! The next program is closely behind and following a similar, expedited time frame. At Alloy, these efficient timelines are more the rule than the exception.
Let’s make great medicines together and go further faster!
Our Proven Approach to Antibody Discovery
1. Proven Success: Alloy boasts a track record of successful partnerships with over 150 companies, featuring four partner programs currently in clinical trials and an additional 35+ programs in the preclinical phase.
2. Speed and Efficiency: Our drug discovery process is renowned for its speed and efficiency, typically completing the discovery phase within 2-3 months. When combined with our comprehensive translational services, it’s possible to progress from hit identification to lead compound development in under nine months.
3. Innovative Platforms and Services: Alloy offers the latest cutting-edge drug discovery technologies including proprietary human, transgenic platforms, ATX-Gx and ATX-CLC, high-velocity antibody discovery, engineering, characterization, and translational services for antibody-based biologics, TCR mimics, and chimeric antigen receptors (CARs).
4. Cost Control & Risk Mitigation: We provide accessible business terms and offer flexible, modular project plans designed to assist portfolio companies in effectively managing costs and mitigating risks while maintaining the highest standards of quality.
Learn More about our Antibody Discovery
Alloy acted as a trusted partner and extension of our team, collaborating with us to optimize an antibody that has now become our lead product candidate.
– Nenad Tomasevic, CEO and Founder, Dren Bio
Alloy is not focused on one solution to a problem, but rather matching the right solution/modality to a problem and enabling others to access these high-quality tools.
– Jürgen Eckhardt, Head of Leaps by Bayer and Pharma BD, Bayer